Últimas noticias sobre Acerinox (OTC:ACRXF) Bolsa

Acerinox SA is a Spain-based stainless steel maker engaged in the manufacture, processing, and marketing of stainless steel products and special alloys. The company operates in two segments; the Stainless steel segment which accounts for the majority of the company's revenue, includes both flat and long stainless steel products, and the High-performance alloys segment includes special alloys with high nickel content. This segment includes all the companies in the VDM Metals subgroup. Geographically the company operates in Spain, the Rest of Europe, America, Africa, Asia, and Others.

ACRXF

Los aranceles al acero afectan de manera desigual a ArcelorMittal y Acerinox. Descubre quién gana y quién pierde en este nuevo escenario.

ArcelorMittal vs. Acerinox: quién gana y quién pierde con los nuevos aranceles de Trump

CLLNY

PUIG BRANDS S.A. U/ADS by PUIG BRANDS S A

PUGBY

SYRVF

Descubre los valores del Ibex 35 con mayor potencial para 2025 y las estrategias clave detrás de sus recomendaciones.

5 valores del Ibex 35 que prometen un crecimiento del 40% o más en 2025

Acerinox SA

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1.png" alt="" class="wp-image-11031" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/18064931/TH-International-0418-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The operator of the Tim Hortons chain in China sold 22 million bagel-based products last year, and said it is aiming to return to revenue and same-store sales growth in 2025
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>TH International's revenue fell 12% in the fourth quarter, moderating from a 17% decline in the previous quarter</li>
<li>The company is targeting a return to revenue growth and achieving breakeven on an EBITDA basis this year</li>
</ul>
The Tim Hortons chain was historically known for donuts, founded in 1964 by its namesake former ice hockey star who also presumably loved the sugary snack. But after yanking the company's core product from most of its menus, the company's China iteration, Tims China, has found better results with bagels, which look similar but lack the sweetness.
Tims China operator&nbsp;TH International Ltd.&nbsp;(THCH.US) has had it rough lately, struggling to differentiate itself from a crowded and fiercely competitive field of premium coffee sellers including everyone from&nbsp;Starbucks&nbsp;(SBUX.US) to local sensations&nbsp;Luckin&nbsp;(LKCNY.US) and&nbsp;Cotti. But the company may have finally found its answer in bagels, based on its&nbsp;<a href="https://www.globenewswire.com/news-release/2025/04/15/3061592/0/en/Tims-China-Announces-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html">latest financial report</a>&nbsp;that mentions the bread-based Western staple numerous times and shows that Tims China may have finally turned a corner in the fourth quarter.
The company said it sold 22 million bagel and bagel sandwich products last year, which averages more than 60 sales per day for each of its roughly 950 stores during the year – not bad for this relatively new differentiator.
Investors seemed to like the chain's new China flavor, sending the company's embattled stock up 18% in three trading days after the announcement this week. Still, the stock has lost about half of its value over the last year and currently trades at a watered-down price-to-sales (P/S) ratio of just 0.45. By comparison, Luckin and&nbsp;Yum China&nbsp;(YUMC.US; 9987.HK), which is also moving aggressively into premium coffee, trade at much higher multiples of 2.08 and 1.52, respectively.
In addition to finding success in bagels, which it serves not only with traditional toppings like cream cheese, but also as a bread substitute for various sandwich-type products, TH International has also found better results with franchising than self-operated stores. That's different from most other restaurant operators, whose self-operated stores are typically more profitable, but choose to also use franchising to expand more quickly and conserve capital.
CFO Li Dong said TH International's franchise business currently contributes "steady cash flows and profitability," even as the company's self-operated stores continue to lose money, resulting in overall operating losses.
As its situation improves, the company is also holding out big hopes for 2025. It is targeting a return to same-store sales and revenue growth, after the important metrics turned negative in early 2024 and remained that way for the rest of the year. It is also aiming to achieve breakeven on an earnings before interest, taxes, depreciation and amortization (EBITDA) basis for all of 2025, which would represent the first time a major profit metric wasn't negative.
"Moving into the spring of 2025, we look forward to regaining growth on our top line and to continue our expansion with plans to open at least 200 stores this year, the majority of which will be through our successful subfranchise (business) while maintaining our focus on operational excellence and profitability," said CEO Lu Yongchen.
<h4 class="wp-block-heading">Third-quarter bottom</h4>
Broadly speaking, TH International's latest results show the company's recent downturn bottomed out in last year's third quarter and it began recovering at the end of the year as it completed some major adjustments to its self-operated stores and its franchise business gained momentum. Its revenue fell 12% to 333 million yuan ($45.6 million) during the quarter from 378 million yuan a year earlier, improving from a 17% decline in the previous quarter.
The story was similar for the company's same-store sales, whose 13.3% decline in the fourth quarter represented an improvement from the 21.7% decline in the third quarter.
The company passed a symbolic milestone during the fourth quarter as it opened its 1,000th&nbsp;store in Shanghai, bringing its total to 1,022 by the end of last year. Six years after coming to China, TH International has a relatively large footprint in the country, with stores in 82 cities.
A deeper dive into the overall store count figure shows the company was aggressively closing underperforming self-operated stores during the first three quarters of last year, with the figure dropping from 619 at the end of 2023 to 564 at the end of last September. But the trend returned to a positive direction in the fourth quarter, as its self-operated store count rose to 576 at the end of last year.
Meantime, the company's franchised store count has grown steadily without pause, rising from 283 at the end of 2023 to 446 at the end of last year, making up 44% of its total. And as we've previously noted, CEO Lu said a majority of the new store openings this year will come from the franchised business, though he wasn't more specific.
While the franchised business is more profitable and looks on track to overtake the company's self-operated stores in terms of store count, the former contributes far less revenue than the latter. TH International said its self-operated stores generated 270 million yuan in the fourth quarter, down 17.7% year-on-year, but still making up 81% of its total. By comparison, its "other revenue," which comes mostly from the franchised store business, rose 25.8% year-on-year during the fourth quarter to 62.5 million yuan, even though it made up just 19% of its total.
The company has also been relatively strong in terms of cost controls, with store costs and expenses down 18.8% year-on-year in the fourth quarter, and marketing expenses down by an even larger 35%.
The combination of cost controls, closure of underperforming stores and new success with its bagel-based formula helped TH International narrow its operating loss to 117 million yuan from 218 million yuan a year earlier, and reduce its net loss to 132 million yuan from 311 million yuan over that time. CFO Li also noted the company is "no longer cash burning like in the past years," and that it has ample funds after receiving new financing from its founding shareholders.
All those signals seem to show that TH International may be emerging from a difficult period as a more focused company that can operate profitably in the not-too-distant future. Now, it just needs to show it can maintain its recent positive momentum in the face of fierce competition and headwinds created by China's slowing economy.

Earnings

Equities

Restaurants

Opinion

Markets

THCH

Tim Hortons China Operator Finds Gamechanger In Bagels

Excelerate Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EE#NYSE">EE</a>) ("Excelerate" or the "Company") today announced that Excelerate Energy Limited Partnership (the "Issuer"), a subsidiary of Excelerate, has commenced an offering (the "Offering") of $700 million in aggregate principal amount of unsecured senior notes due 2030 (the "2030 Notes"). Excelerate intends to use the net proceeds from the Offering, together with the net proceeds from the equity offering previously consummated by the Company and cash on hand, to (i) fund the consideration payable by the Company in the previously-announced pending acquisition of New Fortress Energy, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) business in Jamaica for $1.055 billion, subject to certain adjustments, (ii) repay the outstanding borrowings under the Company's term loan facility, which were $163.6 million as of December 31, 2024, and (iii) pay related fees and expenses.
The 2030 Notes will be guaranteed by certain direct and indirect restricted subsidiaries of the Issuer.

News

Offerings

Excelerate Energy Announces Proposed Offering Of $700M Of Senior Notes Due 2030

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>)&nbsp;disclosed in its 2024 annual report last week that the <a target="_blank" href="https://www.benzinga.com/topic/tsm" rel="noreferrer noopener">U.S. semiconductor technology</a> embargo challenged its ability to ensure complete compliance with the rules.
The Taiwanese contract chipmaker also held the semiconductor sanctions responsible for leading to higher violations of semiconductor sanctions by business partners to gain access to <a target="_blank" href="https://investor.tsmc.com/english/annual-reports" rel="noreferrer noopener">the advanced technology</a>.
Taiwan Semiconductor disclosed it could not guarantee complete compliance.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44852860/nvidia-lam-research-and-marvell-to-face-least-impact-from-tariffs-while-intel-and-arm-could-suffer-more-bofa-analyst" rel="noreferrer noopener">These Semiconductor Stocks To Face Least Tariffs Impact Compared To Intel</a>
Taiwan Semiconductor partners&nbsp;Qualcomm Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>)&nbsp;and&nbsp;MediaTek Inc co-developed mobile chips for phone makers, including&nbsp;Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), as per a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-21/tsmc-warns-of-limits-of-ability-to-keep-its-ai-chips-from-china?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">report</a>. However, a 2024 report by TechInsights&nbsp;revealed&nbsp;the presence of Taiwan Semiconductor technology in Huawei Technology&#8217;s Ascend 910B AI chip.
The U.S. has restricted Huawei&#8217;s access to advanced semiconductor technology since 2020, citing national security threats.
Taiwan Semiconductor disclosed in its annual report that it took every precaution, including restricting shipment to its trading partners, to ensure compliance with the U.S. sanctions.
Taiwan Semiconductor&#8217;s <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">first-quarter revenue</a> rose 41.6% to $25.53 billion, topping the analyst consensus estimate of $23.92 billion, despite a smartphone seasonality impact on sales.
The second-quarter revenue guidance predicts $28.4 billion-$29.2 billion versus the $26.79&nbsp;billion analyst estimate, with strong demand for 3-nm and 5-nm technologies.
In March, Taiwan Semiconductor announced&nbsp;an additional&nbsp;$100 billion&nbsp;investment&nbsp;in U.S. chipmaking (on top of $65 billion in April 2024). The investment followed&nbsp;President Donald Trump&#8217;s verbal attacks&nbsp;on Taiwan &#8220;for stealing&#8221; the U.S. semiconductor business and generating massive trade deficits for Washington.
Price Action:&nbsp;TSM stock is down by 1.91% to $148.85 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44851295/asml-cfo-incorporates-tariff-impact-in-outlook-reveals-strong-demand-for-advanced-euv-and-high-na-systems" target="_blank" rel="noreferrer noopener">ASML CFO Incorporates Tariff Impact In Outlook, Reveals Strong Demand For Advanced EUV And High NA Systems</a></li>
</ul>
Photo by Sundry Photography on Shutterstock

Asia

Government

Regulations

Tech

Media

QCOM

XIACF

XIACY

Taiwan Semiconductor Confronts Challenges Of US Chips Sanction On China

Native health advocates are raising alarms over a proposed federal budget that reduces funding to the Indian Health Service (IHS). In a letter dated April 17 sent to the Health and Human Services Secretary Robert F. Kennedy, Jr., the National Indian Health Board (NIHB) criticized the planned cuts as dangerous and urged urgent rectification.
What Happened: The Office of Management and Budget's (OMB) proposed adjustments include almost a 30% reduction to the IHS base budget from FY 2025 estimates, amounting to approximately $900 million in cuts for FY 2026. The plan also removes advance appropriations, stops funding for water and sanitation and healthcare facility construction, restricts self-governance for new Tribes, and eradicates services across the board.
"We implore you to immediately appeal the proposed reductions… mirroring the swift and decisive action taken by the Secretary of the Interior," the NIHB urged <a href="https://ncuih.org/2025/04/18/ncuih-urges-hhs-to-reconsider-proposed-budget-cuts-to-indian-health-service-and-hhs/">in the letter</a>.
See Also: <a href="https://www.benzinga.com/25/03/44514142/rfk-jr-to-announce-10000-job-cuts-shut-regional-agencies-in-a-major-health-department-overhaul-report">RFK Jr. To Cut 10,000 Jobs, Shut Regional Agencies In Major Health Department Overhaul: Report</a>
Why It Matters: The IHS operates with a 30% vacancy rate at the moment, the letter states. It adds: "if each facility across the IHS lost just one physician-level provider, 43% of those facilities would have to close their doors entirely."
The letter calls the proposed cuts as a direct threat to life. "This loss of funding will lead to deaths in our communities from preventable medical incidents, such as precipitous births, cardiac events, untreated diabetes complications, and preventable suicides," it warns.
The NIHB clarifies that these are not hypotheticals—they are documented outcomes from past underfunding. "Before IHS had advance appropriations… members of our families died from these exact types of preventable emergencies," the letter said.
Secretary Kennedy has previously said Indian health is a top priority. With more than 574 federally recognized Tribal Nations relying on IHS, the NIHB is calling on him to that stay true to that promise by declining the OMB's proposed reductions.
"The funding to the IHS is not an arbitrary budget number," the NIHB wrote. "These figures represent funding to keep doctors and nurses in our facilities nationwide."
Kennedy Jr.&#8217;s <a href="https://www.benzinga.com/25/04/44782857/rfk-jrs-massive-federal-health-workforce-cut-could-take-decades-to-rebuild-warn-experts-we-cannot-accurately-assess-whether-we-are-truly-making-america-healthier">mass layoffs have concerned experts</a>, disrupting crucial health data collection and research, including studies on cancer in firefighters and the transmission of HIV and syphilis from mothers to babies. Attempts to monitor and contain disease outbreaks—like the country&#8217;s worst measles outbreak in decades—have also been impacted.
Earlier this month, Kennedy <a href="https://www.benzinga.com/25/04/44777309/health-secretary-kennedy-raises-concerns-about-taxpayer-funded-care-for-risky-behaviors">stirred controversy</a> in an interview with CBS News, where he asked whether taxpayers should foot the bill for those who smoke regularly or often eat unhealthy foods, like doughnuts.
Read Next: <a href="https://www.benzinga.com/news/25/04/44889497/its-offensive-and-just-plain-wrong-trumps-budget-proposal-to-eliminate-head-start-affecting-over-1-million-p">&#8216;It&#8217;s Offensive And Just Plain Wrong&#8217;—Trump&#8217;s Budget Proposal To Eliminate Head Start, Affecting Over 1 Million Parents</a>
Image Via Shutterstock

Health Care

General

Native Health Leaders Slam Trump Administration's Proposed $900 Million Cuts To Indian Health Service: Call Plan 'Dangerous' In Letter To RFK Jr.

Highly promising survival data from OVATION 2 Study of treatment of newly diagnosed advanced ovarian cancer to be presented&nbsp;
Initiation of Phase 3 trial sites underway for pivotal study of IMNN-001 following alignment on protocol with FDA
LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an abstract highlighting new, highly encouraging, Overall Survival data from the Phase 2 OVATION 2 Study of IMNN-001 to treat women with newly diagnosed advanced ovarian cancer was accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting is being held May 30 - June 3, 2025, in Chicago, Illinois and virtually. IMUNON recently announced alignment with the U.S. Food and Drug Administration (FDA) on the study protocol for the Phase 3 OVATION 3 clinical trial of IMNN-001 and has initiated trial site activation.
IMNN-001, based on the company's proprietary TheraPlas&#xAE; technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IL-12 is a powerful pluripotent cytokine known for inducing strong anti-cancer immunity by promoting T-lymphocyte and natural killer cell proliferation while inhibiting tumor-mediated immune suppression. IMNN-001 is the first and only IL-12 immunotherapy to achieve a clinically effective response including overall survival benefit in frontline treatment in patients with advanced (Stage III/IV) ovarian cancer.
"We are pleased to have the opportunity to present new data from the Phase 2 OVATION 2 Study of IMNN-001 in an oral presentation at ASCO's Annual Meeting," said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. "This recognition underscores the significant potential of IMNN-001 to transform the treatment of women with newly diagnosed advanced ovarian cancer, an underserved population that has not seen treatment innovation in over 25 years, as we advance our Phase 3 program. We look forward to sharing more about our progress during this pivotal stage of development."
Details for the oral presentation are as follows:
Presentation Details
Title: A Phase I/II study of the safety and efficacy of intraperitoneal IMNN-001 in combination with neoadjuvant chemotherapy (NACT) of Paclitaxel and Carboplatin in Patients Newly Diagnosed with Advanced Epithelial Ovarian Cancer (EOC): Updated survival analysts from OVATION-2 trial
Session Title: Rapid Oral Abstract – Gynecologic Cancer
Session Date: June 3, 2025
Session Time: 8:00 AM-9:30 AM CDT

Biotech

IMNN

Imunon Announces That An Abstract Highlighting New Overall Survival Data From Phase 2 Ovation 2 Study Of Imnn-001 To Treat Women With Newly Diagnosed Advanced Ovarian Cancer Was Accepted For Oral Presentation at the 2025 American Society of Clinical Oncology Annual Meeting May 30 - June 3, 2025, In Chicago, Illinois

<h3>Gainers</h3>
<ul>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares increased by 27.8% to $0.99 during Monday's pre-market session. </li>
<li>Lobo EV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) stock increased by 16.42% to $0.85. The company's market cap stands at $7.3 million. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) stock rose 13.11% to $5.78. The company's market cap stands at $1.1 billion. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares rose 10.47% to $0.15. The company's market cap stands at $60.3 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) stock rose 10.29% to $0.0. The company's market cap stands at $2.9 million. </li>
<li>Ethan Allen Interiors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) stock moved upwards by 9.35% to $28.99. The market value of their outstanding shares is at $737.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares declined by 47.1% to $3.62 during Monday's pre-market session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Thunder Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIEV#NASDAQ">AIEV</a>) shares fell 44.09% to $0.08. The company's market cap stands at $3.8 million. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares decreased by 13.91% to $0.2. The market value of their outstanding shares is at $28.7 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares declined by 12.25% to $0.36. The market value of their outstanding shares is at $104.2 million. </li>
<li>American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) shares decreased by 9.61% to $9.41. The market value of their outstanding shares is at $119.8 million. </li>
<li>1-800-Flowers.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) shares decreased by 8.84% to $4.85. The company's market cap stands at $309.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIEV

AOUT

FLWS

LOBO

LXEH

MKDW

NWTN

QVCGA

SHCO

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 39.2% to $1.2 during Monday's pre-market session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 13.26% to $8.88. The company's market cap stands at $14.6 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock moved upwards by 12.79% to $1.41. The company's market cap stands at $5.1 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares rose 12.6% to $0.57. The company's market cap stands at $68.8 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock increased by 11.07% to $0.32. The market value of their outstanding shares is at $9.6 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares increased by 10.97% to $9.2. The market value of their outstanding shares is at $2.7 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock fell 48.3% to $0.14 during Monday's pre-market session. </li>
<li>Adagio Medical Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADGM#NASDAQ">ADGM</a>) shares decreased by 23.02% to $1.37. The market value of their outstanding shares is at $21.1 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock fell 17.6% to $1.78. The market value of their outstanding shares is at $24.4 million. </li>
<li>Cuprina Holdings (Cayman) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUPR#NASDAQ">CUPR</a>) shares fell 16.17% to $4.15. The market value of their outstanding shares is at $87.1 million. </li>
<li>Sensei Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNSE#NASDAQ">SNSE</a>) stock decreased by 15.79% to $0.34. The market value of their outstanding shares is at $8.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) stock decreased by 13.26% to $1.96. The company's market cap stands at $3.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADGM

ALVO

APVO

CUPR

IVVD

PRPH

PRTG

RDHL

SBFM

SNSE

SXTC

VINC

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Intelligent Living (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares moved upwards by 18.7% to $0.43 during Monday's pre-market session. The company's market cap stands at $7.7 million. </li>
<li>Safe Pro Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) stock moved upwards by 17.07% to $2.88. The market value of their outstanding shares is at $43.6 million. </li>
<li>Baiya International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIYA#NASDAQ">BIYA</a>) stock increased by 15.36% to $3.68. The market value of their outstanding shares is at $46.0 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) stock moved upwards by 13.25% to $0.56. The market value of their outstanding shares is at $5.3 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) shares rose 9.33% to $0.19. The market value of their outstanding shares is at $37.7 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Orion Group Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) stock rose 7.01% to $6.41. The market value of their outstanding shares is at $249.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares decreased by 64.7% to $1.82 during Monday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) shares decreased by 15.85% to $0.85. The market value of their outstanding shares is at $65.1 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares declined by 14.41% to $0.11. The company's market cap stands at $15.7 million. </li>
<li>Swvl Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWVL#NASDAQ">SWVL</a>) shares declined by 13.75% to $2.51. The market value of their outstanding shares is at $26.9 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock decreased by 13.11% to $1.52. The company's market cap stands at $21.3 million. </li>
<li>Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) shares fell 13.11% to $5.04. The company's market cap stands at $66.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

BIYA

ILAG

LNZA

SPAI

SWVL

VATE

YGMZ

12 Industrials Stocks Moving In Monday's Pre-Market Session

Seaport Global analyst Michael Harrison maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Buy and lowers the price target from $34 to $31.

Price Target

Analyst Ratings

Seaport Global Maintains Buy on Element Solutions, Lowers Price Target to $31

<h3>Gainers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock moved upwards by 30.8% to $8.87 during Monday's pre-market session. The market value of their outstanding shares is at $88.4 million. </li>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) stock increased by 10.86% to $2.55. The market value of their outstanding shares is at $32.0 million. </li>
<li>Pixelworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXLW#NASDAQ">PXLW</a>) shares moved upwards by 10.57% to $0.59. The company's market cap stands at $37.1 million. </li>
<li>Infobird Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFBD#NASDAQ">IFBD</a>) stock moved upwards by 9.83% to $1.34. The market value of their outstanding shares is at $10.9 million. </li>
<li>Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) stock moved upwards by 9.2% to $1.0. The market value of their outstanding shares is at $17.7 million. </li>
<li>Datavault AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVLT#NASDAQ">DVLT</a>) stock moved upwards by 6.38% to $0.87. The company's market cap stands at $53.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viavi Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) stock fell 44.2% to $5.5 during Monday's pre-market session. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) stock fell 14.87% to $0.32. The market value of their outstanding shares is at $9.2 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) stock declined by 13.48% to $1.99. The market value of their outstanding shares is at $2.3 million. </li>
<li>NOVONIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVX#NASDAQ">NVX</a>) stock decreased by 12.72% to $1.03. The market value of their outstanding shares is at $163.7 million. </li>
<li>ARB IOT Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) shares declined by 9.15% to $0.69. The market value of their outstanding shares is at $18.2 million. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) shares fell 8.57% to $0.36. The market value of their outstanding shares is at $50.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBB

DVLT

IFBD

INUV

MLGO

Nuveen California Dividend Advantage Municipal Fund 2

PXLW

SAGT

SMSI

VIAV

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Acquisition aims to provide broader access to comprehensive testing and laboratory services for patients and physicians in North Mississippi &nbsp;
BURLINGTON, N.C. (April 21, 2025) –&nbsp;<a href="https://www.labcorp.com/">Labcorp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>),&nbsp;a global leader of innovative and comprehensive laboratory services, and North Mississippi Health Services announced today that Labcorp has completed its acquisition of North Mississippi Health Services' ambulatory outreach laboratory business and become a referral laboratory for its seven hospitals and clinic laboratories. &nbsp; Through this acquisition, North Mississippi Health Services' patients and providers will have continuity of high-quality laboratory services and access to Labcorp's leading clinical laboratory services, robust data and digital tools.&nbsp;In addition, Labcorp will open three new patient service centers in Tupelo, West Point and Amory by mid-year to increase availability of laboratory services in North Mississippi.&nbsp;

Laboratory Corporation Of America Holdings

Reported April 18, 2025: Labcorp Acquires Select Assets Of North Mississippi Health Services' Ambulatory Outreach Laboratory Business; No Financial Terms Disclosed

Company Completes International Filings for Protection Under Patent Cooperation Treaty for Expanded Global Protection to Rapidly Identify and Map Small Lethal Threats Using AI and Drone Imagery
Safe Pro Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPAI#NASDAQ">SPAI</a>) ("Safe Pro" or the "Company"), a leader in artificial intelligence (AI)-powered defense and security solutions, today announced that it has completed the filing of the national phase patent applications for nearly 50 jurisdictions, claiming priority to International Patent Application No. PCT/US2023/029909, published on March 21, 2024.
The Company's IP portfolio currently includes the awarded <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsafeprogroup.com%2Fsafe-pro-awarded-us-patent-for-disruptive-ai-drone-imagery-technology-a-groundbreaking-innovation-helping-to-protect-millions-of-lives-globally%2F&amp;esheet=54240804&amp;newsitemid=20250421927903&amp;lan=en-US&amp;anchor=US+Patent+No.+12%2C146%2C729+incorporating+21+claims+made+in+the+Company%26%238217%3Bs+original+patent+application+entitled%2C+%26%238220%3BSystems+and+Methods+for+Detecting+and+Identifying+Explosives.%26%238221%3B&amp;index=1&amp;md5=6d75db99deafa929fc3253423541dc67">US Patent No. 12,146,729 incorporating 21 claims made in the Company's original patent application entitled, "Systems and Methods for Detecting and Identifying Explosives."</a> These claims cover autonomous detection, identification, and labeling of explosives in orthomosaic images using AI processing of drone imagery. Valid until 2043, the patent captures the groundbreaking nature of SpotlightAI&#x2122; and its ability to transform fields ranging from humanitarian demining, agriculture, to national defense and reconstruction. The Company has now expanded its international filings by entering in the national phase of its previously filed (and related) international application filed with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.wipo.int%2Fportal%2Fen%2F&amp;esheet=54240804&amp;newsitemid=20250421927903&amp;lan=en-US&amp;anchor=World+Intellectual+Property+Organization+%28WIPO%29&amp;index=2&amp;md5=c63d9b6f57f38e5b616b28488a220186">World Intellectual Property Organization (WIPO)</a> under the Patent Cooperation Treaty ("PCT"), in Europe (extended to include Bosnia and Herzegovina), Canada, Australia, New Zealand, Japan, Israel and Ukraine; which covers patent protection rights in 47 jurisdictions.

Safe Pro Group Completes Filing Of National Phase Patent Applications For Nearly 50 Jurisdictions

ELUT

Elutia Initiates EluPro Registry Study To Collect Patient Outcome Data

Chipotle Signs Agreement With Restaurant Operator Alsea To Open Restaurants In Mexico, Beginning With A Location By Early 2026

- Cybin will leverage Osmind's 800-clinic network, point-of-care software, and real-world data to support the commercial preparation for its clinical-stage pipeline -
- Osmind is a leading service provider to psychiatry practices in the U.S. focused on advancing psychiatry through technology and services to bring innovative mental health treatments to patients in need -
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54239475&amp;newsitemid=20250416179232&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=d22113092709043bd0460cb33277a431">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced a strategic partnership with Osmind, a leading service provider advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need.
"Preparation for the commercialization of our clinical stage programs is a top priority, and aligning ourselves with Osmind will help us accelerate our goals," said Doug Drysdale, Chief Executive Officer of Cybin. "Osmind's extensive network of over 800 psychiatry clinics in the U.S., combined with our expertise, allows us to align on and prepare for the operational infrastructure needs relevant for interventional treatments. End-to-end mapping in key areas of clinic workflow and patients' journey such as pharmacy, fulfillment, patient access and reimbursement will lay the groundwork for commercialization of our lead clinical programs: CYB003 in Phase 3 development for the adjunctive treatment of major depressive disorder, and CYB004 in a Phase 2 study for generalized anxiety disorder. We look forward to a productive collaboration that leads to meaningful progress in transforming the treatment paradigm for patients with mental health disorders."
With 52.9 million people in the U.S., or nearly one in five Americans1, living with a mental illness, there remains a significant unmet need in addressing the mental health crisis. Many patients do not experience relief with the standard of care, highlighting a need for innovation and improved therapeutic options.
"We are thrilled to partner with Cybin; together, we are aligning incentives across stakeholders to help patients in need," said Jimmy Qian, President of Osmind. "By preparing real-world care settings for next-generation neuropsychiatric interventions, Osmind is reducing friction and promoting practice success for clinicians, increasing access for patients, while supporting Cybin's market penetration and commercial launch. Osmind and Cybin share a common mission to scale cutting-edge mental health treatments to as many patients as possible. We are delighted to support Cybin's differentiated research, development, and commercialization efforts."
Opportunity to Address Unmet Needs in Mental Health
<ul>
<li>Globally, it is estimated that over 300 million people suffer from major depressive disorder (MDD)2. The global market size for major depressive disorder was estimated at $5.15 billion in 2024 and is projected to rise to $11.09 billion by 2033.3</li>
<li>An estimated 21 million Americans experienced at least one major depressive episode in 2021.4 About two-thirds of patients with MDD do not experience relief with initial antidepressant treatment.5</li>
<li>It is estimated that 6.8 million people in the U.S. suffer from generalized anxiety disorder ("GAD").6 Approximately 50% of patients with GAD are unresponsive to first line treatment with selective serotonin reuptake inhibitors ("SSRIs") and serotonin-norepinephrine reuptake inhibitors ("SNRIs").7</li>
</ul>

Contracts

CYBN

Cybin Entyers Strategic Partnership With Osmind To Help Bring Innovative Mental Health Treatments To Patients In Need

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) announced on Monday that it is stepping deeper into the floral business with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44893128/target-launches-new-fresh-floral-brand" rel="noreferrer noopener">official launch of its first standalone</a> flower and plant brand, Good Little Garden.
With prices starting at $6, the brand offers year-round access to a variety of blooms and greens, catering to both special occasions and everyday moments.
Good Little Garden introduces over 60 varieties of fresh-cut flowers and potted plants to Target's lineup.
Shoppers can now find arrangements featuring roses, tulips, and carnations, as well as potted orchids and succulents, both in stores across the country and via same-day fulfillment options.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44850301/target-under-pressure-from-discretionary-spend-slowdown-mounting-inventory-risk-goldman-sachs-downgrades-stock" rel="noreferrer noopener">Target Under Pressure From Discretionary Spend Slowdown, Mounting Inventory Risk, Goldman Sachs Downgrades Stock</a>
Prices range from $6 for fresh-cut flowers to $15 and up for potted varieties, with seasonal themes that adjust throughout the year to match holidays and seasonal trends.
"When you combine the amazing assortment our team has curated, and everything we've done to ensure we're delivering quality and freshness to stores nationwide, Good Little Garden is making it easier than ever to celebrate any occasion," said executive vice president and chief merchandising officer of food, essentials and beauty, Lisa Roath.
Customers can also shop Good Little Garden products through Target's convenient Drive Up and Order Pickup options. Target Circle 360 members get the added benefit of free same-day delivery for qualifying orders.
Since introducing flowers under its Spritz party brand in 2020, Target has experienced considerable growth in its floral department.
Sales of flowers and plants have surged, tripling in recent years, which has led the company to broaden its selection.
Price Action: TGT shares traded lower by 0.60% at $92.55 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44876406/retail-slowdown-and-tariff-turbulence-hit-leisure-stocks-says-analyst" target="_blank" rel="noreferrer noopener">Retail Slowdown, Tariffs Jolt Leisure Stocks: Analyst Revises Estimates For Topgolf, Harley-Davidson And More</a></li>
</ul>
Photo by bluestork via Shutterstock

Target Rolls Out Standalone Flower Brand 'Good Little Garden'

&nbsp;ASA's Readoption of the Poison Pill Followed the Court's March 28th Ruling that the Pill Violates the Investment Company Act of 1940
ASA's Poison Pill Has Remained in Continuous Effect for More Than 474 Days, Harming Shareholders and Violating Federal Law
Saba Believes the Anti-Shareholder Actions and Unlawful Steps Taken by Chair Mary Joan Hoene and Director William Donovan Underscore the Need for Immediate Board Change
Saba Capital Management, L.P. (together with certain of its affiliates, "Saba"), the largest common shareholder of ASA Gold and Precious Metals Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASA#NYSE">ASA</a>) ("ASA" or the "Fund") with 17.2% ownership of the Fund's outstanding shares, today announced that it has filed a lawsuit in the United States District Court for the Southern District of New York (the "Court") against ASA and the legacy members of its Board of Directors (the "Board") – Mary Joan Hoene and William Donovan – regarding their readoption of an unlawful shareholder rights plan after the Court ruled that the previous shareholder rights plan violated the Investment Company Act of 1940 (the "'40 Act").

Legal

Saba Capital Files Lawsuit Against ASA Gold And Precious Metals And Its Legacy Directors Over Latest Unlawful Poison Pill; Says "ASA's Poison Pill Has Remained in Continuous Effect for More Than 474 Days, Harming Shareholders and Violating Federal Law"

Hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the publication of findings from the prevalence phase of the CATALYST trial in Diabetes Care, a peer-reviewed journal published by the American Diabetes Association.
The publication, Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes, can be accessed at: <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdiabetesjournals.org%2Fcare%2Flookup%2Fdoi%2F10.2337%2Fdc24-2841&amp;index=1&amp;md5=93462c6dd5567a9a85f2e87e65dc5785">https://diabetesjournals.org/care/lookup/doi/10.2337/dc24-2841</a>.
CATALYST was the largest and most rigorous trial ever conducted to assess the prevalence of hypercortisolism (Cushing's syndrome) in patients with difficult-to-control type 2 diabetes. Part one of the study screened 1,057 patients at 36 sites across the United States. All patients had hemoglobin A1c greater than 7.5 percent, despite receiving multiple glucose-lowering therapies, including GLP-1 receptor agonists. Using a simple, standardized 1-mg dexamethasone suppression test (DST), 24 percent of these patients were found to have hypercortisolism. These findings were first presented at the American Diabetes Association Scientific Sessions in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.corcept.com%2Fnews-releases%2Fnews-release-details%2Fcorcept-announces-presentation-results-prevalence-phase-catalyst&amp;esheet=54240352&amp;newsitemid=20250421854008&amp;lan=en-US&amp;anchor=June+2024&amp;index=2&amp;md5=12702a0e0a0fa0edd714c70e67cb4916">June 2024</a>.

CORT

Corcept Therapeutics Announces Publication Of Findings From Prevalence Phase Of CATALYST Trial In Diabetes Care

Southern States (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.97 by 6.19 percent. This is a 14.44 percent increase over earnings of $0.90 per share from the same period last year.

Earnings Beats

SSBK

Southern States Q1 Adj EPS $1.03 Beats $0.97 Estimate

Mega Matrix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPU#NYSE">MPU</a>) announced that Yuder Pte. Ltd. ("Yuder"), a indirectly wholly owned subsidiary of it, has signed a Memorandum of Understanding (MOU) with Interactive Films LLC ("Interactive Films"), a subsidiary of Snail, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAL#NASDAQ">SNAL</a>) ("Snail Games"), a leading global independent developer and publisher of interactive digital entertainment. Under this MOU, both parties will leverage their respective strengths to establish a comprehensive collaboration framework for the joint development, production, and global distribution of short dramas, further enhancing their presence in the entertainment industry.

SNAL

Mega Matrix Subsidiary Yuder Signs MOU With Snail Games' Interactive Films To Jointly Develop, Produce, And Distribute Short Dramas Globally

Acerinox

Comments

Acerinox

Noticias

Últimas noticias sobre Acerinox (OTC:ACRXF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL